GO:0042985 negative regulation of amyloid precursor protein biosynthetic process: APP Synthesis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042985 describes any process that stops, prevents, or reduces the formation of amyloid precursor protein (APP), the precursor of amyloid-beta.
• APP is a type I transmembrane glycoprotein whose sequential cleavage by beta- and gamma-secretases generates amyloid-beta, the peptide that aggregates in Alzheimer disease.
• Negative regulation of APP biosynthesis can occur at transcriptional, post-transcriptional, and autophagic degradation levels, and PPARA-mediated autophagy reduces APP/amyloid-beta pathology in murine models.
• The APP intracellular domain (AICD) feeds back on transcription, including FOXO3a-dependent regulation of adult hippocampal neurogenesis.
• APP biology extends beyond the brain: platelet APP modulates venous thromboembolism in mice, and APP competes with HIV-1 Gag for VPS4A and TSG101 during viral budding.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of candidate regulators of APP biosynthesis.
Description
GO:0042985, negative regulation of amyloid precursor protein biosynthetic process, is a Gene Ontology biological process term that captures any cellular mechanism which stops, prevents, or reduces the frequency, rate, or extent of the chemical reactions and pathways that produce amyloid precursor protein (APP), the precursor of amyloid-beta. APP is a ubiquitously expressed type I transmembrane protein that is sequentially cleaved by beta-secretase and gamma-secretase to release amyloid-beta, the peptide that accumulates in Alzheimer disease brains. Because APP levels set the ceiling for amyloid-beta production, understanding how cells restrain APP biosynthesis is central to Alzheimer disease biology and to therapeutic strategies aimed at lowering amyloid-beta. The term is mechanistically broad: it includes transcriptional repression of the APP gene, post-transcriptional control of APP mRNA stability or translation, and enhanced degradation or clearance of APP protein. For example, activation of PPARA induces autophagy and reduces APP/amyloid-beta pathology and cognitive decline in a murine Alzheimer model, while the APP intracellular domain (AICD) can regulate transcription factors such as FOXO3a and thereby influence adult hippocampal neurogenesis. APP also participates in non-neuronal biology, including platelet-dependent venous thromboembolism and competition with HIV-1 Gag for the ESCRT machinery components VPS4A and TSG101. For researchers, GO:0042985 provides a controlled vocabulary to annotate genes, pathways, and perturbations that lower APP output. It is used in enrichment analyses of transcriptomic and proteomic datasets, in functional annotation of CRISPR screens, and in mechanistic studies of neurodegeneration, neuroinflammation, and viral-host interactions. This article reviews the definition, mechanisms, key genes, disease links, and experimental methods relevant to GO:0042985.
negative regulation of amyloid precursor protein biosynthetic process At A Glance
| GO ID | GO:0042985 |
|---|---|
| GO term | negative regulation of amyloid precursor protein biosynthetic process |
| Ontology | biological_process |
| Synonym | negative regulation of APP biosynthetic process; inhibition of amyloid precursor protein biosynthetic process; downregulation of amyloid precursor protein biosynthetic process |
| Major function | Reduces the frequency, rate, or extent of APP biosynthesis, thereby limiting amyloid-beta precursor availability |
| Biological context | Neuronal and non-neuronal cells; relevant to Alzheimer disease, neurogenesis, platelet biology, and viral budding |
| Representative regulators | PPARA-mediated autophagy, AICD/FOXO3a signaling, alpha-secretase-dependent Fe65 nuclear localization |
| Related disease | Alzheimer disease and other amyloid-related pathologies |
| Research methods | CRISPR KO/point mutation/KI/overexpression, RNA-seq, proteomics, autophagy flux assays, amyloid-beta ELISA |
What Is GO:0042985?
In plain terms, GO:0042985 describes any cellular process that reduces how much amyloid precursor protein (APP) the cell makes or accumulates. The official QuickGO definition is: any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of amyloid precursor protein (APP), the precursor of amyloid-beta. This includes inhibition of APP gene transcription, destabilization or reduced translation of APP mRNA, and accelerated degradation or clearance of APP protein, all of which lower the substrate available for amyloid-beta generation.
Why Is negative regulation of amyloid precursor protein biosynthetic process Important in Cell Biology?
GO:0042985 matters because APP is the obligatory precursor of amyloid-beta, and the amount of APP produced directly influences amyloid-beta generation and aggregation in Alzheimer disease. Interventions that reduce APP biosynthesis, such as PPARA-mediated autophagy activation, reduce Alzheimer-like pathology and cognitive decline in murine models. Moreover, APP is not only a neuronal protein: it modulates venous thromboembolism in mice and competes with HIV-1 Gag for ESCRT components, linking APP biosynthesis to viral replication. Understanding negative regulation of APP biosynthesis therefore has implications for neurodegeneration, vascular biology, and host-pathogen interactions, and it provides a tractable entry point for therapeutic strategies that lower amyloid-beta at its source.
• APP is the precursor of amyloid-beta, so reducing APP biosynthesis lowers the substrate for amyloid plaque formation.
• PPARA-mediated autophagy reduces APP/amyloid-beta pathology and cognitive decline in a murine Alzheimer model.
• AICD-dependent regulation of FOXO3a links APP processing to adult hippocampal neurogenesis.
• Platelet APP modulates venous thromboembolism in mice, showing that APP biosynthesis control has vascular relevance.
• APP competes with HIV-1 Gag for VPS4A and TSG101, connecting APP trafficking/biosynthesis to viral budding.
• Astrocytic Mettl14 depletion attenuates astrogliosis via DUSP1/MAPK in APP/PS1 mice, illustrating glial contributions to APP-related pathology.
• Alpha-secretase-dependent nuclear localization of Fe65 promotes DNA repair, linking APP-binding proteins to genome maintenance.
• Plasma phospho-tau217 is an emerging diagnostic biomarker for Alzheimer disease, underscoring the clinical need to understand APP pathway regulation.
• GO:0042985 enables functional annotation of CRISPR screens and omics datasets aimed at identifying APP-lowering interventions.
• The term provides a controlled vocabulary for cross-study comparison of APP biosynthesis regulators.
What Happens During negative regulation of amyloid precursor protein biosynthetic process?
Transcriptional repression of APP
In simple terms: The cell makes fewer APP mRNA copies by turning down the APP gene.
Negative regulation of APP biosynthesis can begin at the level of transcription, where reduced APP promoter activity or increased repressor activity lowers APP mRNA levels. The APP intracellular domain (AICD), generated by gamma-secretase cleavage, can translocate to the nucleus and influence transcription factor activity, including FOXO3a, which regulates adult hippocampal neurogenesis. This feedback loop illustrates how APP processing products can feed back on APP pathway gene expression. In addition, alpha-secretase-dependent nuclear localization of the APP-binding protein Fe65 promotes DNA repair, indicating that APP-related transcriptional complexes participate in genome maintenance.
Post-transcriptional and translational control of APP mRNA
In simple terms: Even if APP mRNA is made, the cell can stop it from being translated into protein.
APP mRNA stability and translation efficiency are regulated by RNA-binding proteins and microRNAs. Although specific microRNA regulators of APP are not covered by the verified citations here, the general principle is that reduced APP mRNA half-life or translation initiation lowers APP protein output. This level of control is part of GO:0042985 because it reduces the frequency or rate of APP biosynthetic reactions. Researchers can measure this using RNA-seq, polysome profiling, and reporter assays, and can perturb candidate regulators with CRISPR knockout or overexpression.
Autophagic and lysosomal degradation of APP
In simple terms: The cell recycles APP protein through autophagy, reducing how much APP is available.
Activation of PPARA induces autophagy and reduces Alzheimer disease-like pathology and cognitive decline in a murine model, demonstrating that enhancing autophagic clearance of APP and amyloid-beta lowers APP pathway output. Autophagy contributes to negative regulation of APP biosynthesis by removing APP protein and by limiting its access to secretases. This mechanism is particularly relevant because it can be pharmacologically stimulated, making it an attractive target for therapeutic intervention.
Competition for trafficking and ESCRT machinery
In simple terms: APP competes with other proteins for the cellular machinery that moves it around.
APP trafficking and processing intersect with the endosomal sorting complexes required for transport (ESCRT) machinery. HIV-1 Gag competes with APP for VPS4A and TSG101, and this negative interplay affects APP trafficking and viral budding. Such competition can indirectly reduce APP biosynthesis or its conversion to amyloid-beta by diverting APP from secretase-rich compartments. This highlights that negative regulation of APP biosynthesis can occur through indirect, competition-based mechanisms in addition to direct transcriptional or degradative control.
Glial and neuroinflammatory modulation of APP pathways
In simple terms: Brain immune cells can influence how much APP-related pathology develops.
Astrocytic Mettl14 depletion enhances cognitive function by attenuating astrogliosis via the DUSP1/MAPK pathway in APP/PS1 mice, indicating that glial cells modulate APP-related pathology and neuroinflammation. Although this study focuses on astrogliosis rather than APP biosynthesis per se, it demonstrates that non-neuronal cells can shape the APP pathway environment. Negative regulation of APP biosynthesis may therefore be influenced by neuroinflammatory signaling, and glial-specific perturbations are valuable for dissecting these contributions.
Key Genes Involved in GO:0042985 negative regulation of amyloid precursor protein biosynthetic process
The following genes and proteins are experimentally linked to APP biosynthesis, processing, or its negative regulation, based on the verified citations.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APP | Encodes amyloid precursor protein, the substrate for amyloid-beta generation | Core gene of GO:0042985; KO and point-mutation models reveal APP function |
| PPARA | Nuclear receptor that induces autophagy and reduces APP/amyloid-beta pathology | Target for pharmacological activation to lower APP pathway output |
| FOXO3a | Transcription factor regulated by AICD; influences adult hippocampal neurogenesis | Links APP processing to neurogenesis and transcriptional control |
| Fe65 | APP-binding protein; alpha-secretase-dependent nuclear localization promotes DNA repair | Connects APP to genome maintenance and nuclear signaling |
| VPS4A | ESCRT machinery component competed for by HIV-1 Gag and APP | Relevant to APP trafficking and viral budding |
| TSG101 | ESCRT-I component competed for by HIV-1 Gag and APP | Relevant to APP trafficking and viral budding |
| METTL14 | RNA methyltransferase; astrocytic depletion attenuates astrogliosis in APP/PS1 mice | Links epitranscriptomic regulation to APP-related pathology |
| DUSP1 | MAPK phosphatase downstream of Mettl14 in astrocytes | Modulates neuroinflammation in APP/PS1 models |
| MAPK pathway | Signaling cascade affected by Mettl14 depletion in astrocytes | Potential target for modulating APP-related neuroinflammation |
| PSEN1 | Gamma-secretase component; APP/PS1 mice co-express mutant PSEN1 | Common model for amyloid pathology and APP processing |
| BACE1 | Beta-secretase that cleaves APP to initiate amyloid-beta generation | Therapeutic target upstream of amyloid-beta; not directly covered by verified citations but implied by APP processing |
| APOE | Lipid transport protein and major Alzheimer risk factor; not directly cited here | Context for APP/amyloid biology; cite only with additional verified sources |
| Tau | Microtubule-associated protein; plasma phospho-tau217 is an Alzheimer biomarker | Biomarker context for APP pathway studies |
| Amyloid-beta | Peptide product of APP cleavage that aggregates in Alzheimer disease | Readout of APP biosynthesis and processing |
| Autophagy machinery | Mediates degradation of APP and amyloid-beta upon PPARA activation | Target for enhancing negative regulation of APP biosynthesis |
| Alpha-secretase | Cleaves APP in the non-amyloidogenic pathway; influences Fe65 nuclear localization | Relevant to APP processing and DNA repair |
| Gamma-secretase | Cleaves APP to release AICD and amyloid-beta | Produces AICD that regulates FOXO3a and neurogenesis |
How Is negative regulation of amyloid precursor protein biosynthetic process Regulated?
Negative regulation of APP biosynthesis is controlled at multiple levels. PPARA activation induces autophagy, which reduces APP/amyloid-beta pathology and cognitive decline in a murine Alzheimer model, indicating that nuclear receptor signaling can upregulate autophagic clearance of APP. The APP intracellular domain (AICD) generated by gamma-secretase can regulate FOXO3a, a transcription factor that inhibits adult hippocampal neurogenesis, providing a feedback mechanism by which APP processing influences gene expression. Alpha-secretase-dependent nuclear localization of Fe65 promotes DNA repair, linking APP-binding proteins to nuclear signaling and genome maintenance. In addition, HIV-1 Gag competes with APP for VPS4A and TSG101, suggesting that viral proteins can indirectly modulate APP trafficking and availability. Astrocytic Mettl14 depletion attenuates astrogliosis via the DUSP1/MAPK pathway in APP/PS1 mice, indicating that epitranscriptomic and MAPK signaling in glia can shape APP-related pathology. Together, these mechanisms illustrate that negative regulation of APP biosynthesis is integrated with autophagy, transcription factor networks, ESCRT trafficking, and neuroinflammatory signaling.
negative regulation of amyloid precursor protein biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APP | Alzheimer disease; amyloid-beta precursor | APP knockout and knock-in mice; APP/PS1 transgenic mice |
| PPARA | Alzheimer disease; autophagy-mediated clearance | PPARA agonist treatment in APP/PS1 mice; PPARA KO |
| FOXO3a | Adult hippocampal neurogenesis; cognitive function | FOXO3a KO and AICD-dependent reporter assays |
| Fe65 | DNA repair; APP nuclear signaling | Fe65 KO and alpha-secretase perturbation |
| METTL14 | Astrogliosis and neuroinflammation in APP/PS1 mice | Astrocyte-specific Mettl14 KO in APP/PS1 background |
Alzheimer disease
Alzheimer disease is characterized by amyloid-beta plaques derived from APP, and plasma phospho-tau217 is an emerging diagnostic biomarker. Negative regulation of APP biosynthesis is directly relevant because lowering APP production reduces the substrate for amyloid-beta generation. PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model, demonstrating that enhancing negative regulation of APP biosynthesis can be therapeutic. AICD-dependent regulation of FOXO3a inhibits adult hippocampal neurogenesis, linking APP processing to cognitive dysfunction. Astrocytic Mettl14 depletion enhances cognitive function in APP/PS1 mice, further supporting the role of glial and epitranscriptomic regulation in APP-related pathology.
Vascular and thrombotic disease
Platelet APP is a modulator of venous thromboembolism in mice, indicating that APP biology extends beyond the central nervous system. Negative regulation of APP biosynthesis in platelets or megakaryocytes could influence thrombotic risk, although direct evidence for this specific mechanism is not provided by the verified citations. This highlights the need for further research into how APP biosynthesis control affects vascular biology.
Viral infection and host-pathogen interactions
HIV-1 Gag competes with APP for VPS4A and TSG101, and this negative interplay affects APP trafficking and viral budding. This suggests that APP biosynthesis and trafficking are intertwined with host defense and viral replication. Modulating negative regulation of APP biosynthesis could therefore have implications for viral pathogenesis, although the therapeutic relevance remains to be established.
Neuroinflammation and glial biology
Astrocytic Mettl14 depletion attenuates astrogliosis via the DUSP1/MAPK pathway in APP/PS1 mice, improving cognitive function. This indicates that neuroinflammatory signaling in glia can modulate APP-related pathology. Negative regulation of APP biosynthesis may be influenced by glial activation states, and targeting glial pathways could complement neuronal strategies to lower APP output.
From negative regulation of amyloid precursor protein biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase APP biosynthesis? | CRISPR knockout in neuronal cell lines or iPSC-derived neurons, followed by APP ELISA and qPCR |
| Does a specific point mutation in APP alter its biosynthesis or processing? | CRISPR point-mutation knock-in of APP variants in cell lines or mice |
| Does a disease-associated variant affect APP regulation? | Knock-in of the variant using CRISPR homology-directed repair, then measure APP and amyloid-beta |
| Where and when is a candidate regulator expressed relative to APP? | Tagged knock-in (e.g., GFP or HA) of the candidate gene, followed by imaging and co-IP |
| Does overexpression of a regulator reduce APP levels? | CRISPR overexpression (e.g., CRISPRa) or lentiviral overexpression, then measure APP and amyloid-beta |
| Can autophagy activation lower APP in vivo? | PPARA agonist treatment in APP/PS1 mice, with behavioral and biochemical readouts |
How to Study the negative regulation of amyloid precursor protein biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome-wide changes in APP and related genes | Identify negative regulators of APP biosynthesis |
| Proteomics | Protein abundance and interactions | Discover APP-interacting proteins and degradation machinery |
| Autophagy flux assay (LC3-II, p62) | Autophagic degradation activity | Assess PPARA-mediated APP clearance |
| APP/amyloid-beta ELISA | Levels of APP and amyloid-beta peptides | Quantify impact of CRISPR perturbations |
| Plasma phospho-tau217 assay | Alzheimer disease biomarker in blood | Clinical correlation with APP pathway changes |
| Immunofluorescence | Subcellular localization of APP, Fe65, FOXO3a | Study nuclear signaling and DNA repair |
| Co-immunoprecipitation | Protein-protein interactions (e.g., APP-VPS4A) | Dissect competition for ESCRT machinery |
| Behavioral tests (Morris water maze) | Cognitive function in mice | Evaluate therapeutic effects of APP-lowering interventions |
Transcriptomic and proteomic profiling
RNA-seq and quantitative proteomics can identify genes and proteins whose expression correlates with APP levels. In the context of GO:0042985, researchers can compare APP-high versus APP-low conditions to nominate negative regulators. PPARA-mediated autophagy studies used biochemical and behavioral readouts to show reduced APP/amyloid-beta pathology. Astrocytic Mettl14 depletion studies used transcriptomic and pathway analyses to link DUSP1/MAPK signaling to APP/PS1 pathology.
Autophagy flux and degradation assays
Because autophagy contributes to APP clearance, measuring autophagic flux (e.g., LC3-II turnover, p62 levels) is essential. PPARA activation induces autophagy and reduces APP/amyloid-beta pathology in a murine model, so autophagy flux assays are directly relevant to GO:0042985. Combining flux assays with APP protein half-life measurements can distinguish reduced synthesis from enhanced degradation.
Amyloid-beta and APP quantification
ELISA and immunoblotting for APP and amyloid-beta are standard readouts. Plasma phospho-tau217 is a clinically validated biomarker for Alzheimer disease and can complement APP measurements in translational studies. In cell models, APP and amyloid-beta levels are used to assess the impact of CRISPR perturbations on GO:0042985.
Imaging and nuclear signaling assays
Alpha-secretase-dependent nuclear localization of Fe65 promotes DNA repair, so imaging-based assays for nuclear translocation and DNA repair foci are useful. AICD-dependent regulation of FOXO3a can be studied with luciferase reporters and immunofluorescence for FOXO3a localization. These methods help dissect the nuclear signaling arm of APP pathway regulation.
How CRISPR Can Be Used to Study GO:0042985 negative regulation of amyloid precursor protein biosynthetic process
Knockout
CRISPR knockout of candidate negative regulators can test whether loss of function increases APP biosynthesis. For example, knocking out PPARA would be expected to reduce autophagy-mediated APP clearance, potentially increasing APP and amyloid-beta levels. Knockout of Fe65 or FOXO3a can reveal their roles in APP-related nuclear signaling and neurogenesis. Knockout models are essential for establishing causality in GO:0042985.
Point Mutation
Point mutations in APP or its regulators can mimic disease-associated variants. CRISPR point-mutation knock-in allows precise introduction of single-nucleotide changes to test effects on APP biosynthesis and processing. For example, mutations that alter APP cleavage sites or regulatory phosphorylation sites can be modeled to understand their impact on amyloid-beta production.
Knock-in
Knock-in of tagged versions of APP or its regulators (e.g., GFP, HA, or luciferase) enables real-time tracking of protein localization and turnover. Tagged knock-in of Fe65 can be used to monitor alpha-secretase-dependent nuclear localization and DNA repair function. Knock-in of disease-associated variants in APP or PSEN1 can create more physiologically relevant Alzheimer models.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can test whether increasing a candidate regulator reduces APP biosynthesis. Overexpression of PPARA or autophagy components may enhance APP clearance and lower amyloid-beta. Overexpression of AICD or FOXO3a can probe feedback regulation of APP pathway genes. These models complement knockout studies to establish bidirectional control.
How EDITGENE Supports negative regulation of amyloid precursor protein biosynthetic process Research
Researchers studying negative regulation of amyloid precursor protein biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in APP biosynthesis, processing, or clearance. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models, enabling rigorous functional validation of GO:0042985 regulators.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of amyloid precursor protein biosynthetic process research.
Frequently Asked Questions About negative regulation of amyloid precursor protein biosynthetic process
What is GO:0042985?
GO:0042985 is the Gene Ontology term for negative regulation of amyloid precursor protein biosynthetic process, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of APP formation.
What genes are involved in negative regulation of amyloid precursor protein biosynthetic process?
Genes experimentally linked to this process include APP itself, PPARA, FOXO3a, Fe65, VPS4A, TSG101, METTL14, and DUSP1, based on studies of autophagy, AICD signaling, ESCRT competition, and astrogliosis.
How is APP biosynthesis negatively regulated?
APP biosynthesis can be reduced by transcriptional repression, post-transcriptional mRNA destabilization, inhibition of translation, and enhanced autophagic or lysosomal degradation of APP protein.
Why is negative regulation of APP biosynthesis important in Alzheimer disease?
APP is the precursor of amyloid-beta, so reducing APP biosynthesis lowers the substrate for amyloid plaque formation; PPARA-mediated autophagy reduces Alzheimer-like pathology and cognitive decline in mice.
What role does PPARA play in APP regulation?
PPARA activation induces autophagy, which reduces APP/amyloid-beta pathology and cognitive decline in a murine Alzheimer model.
How does AICD regulate APP-related genes?
The APP intracellular domain (AICD) can regulate transcription factors such as FOXO3a, which inhibits adult hippocampal neurogenesis.
Is APP involved in diseases outside the brain?
Yes, platelet APP modulates venous thromboembolism in mice, and APP competes with HIV-1 Gag for VPS4A and TSG101 during viral budding.
What experimental models are used to study GO:0042985?
Common models include CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression cell lines, as well as APP/PS1 transgenic mice and autophagy flux assays.
What biomarkers relate to APP pathway regulation?
Plasma phospho-tau217 is an emerging Alzheimer disease biomarker that can complement APP and amyloid-beta measurements in translational studies.
How can CRISPR screens identify negative regulators of APP biosynthesis?
Genome-wide CRISPR knockout or activation screens can nominate genes whose loss or gain alters APP levels; candidates are then validated with targeted knockout, point mutation, knock-in, or overexpression models.
Conclusion
GO:0042985, negative regulation of amyloid precursor protein biosynthetic process, is a biologically and clinically important Gene Ontology term because it directly controls the availability of APP, the precursor of amyloid-beta. Mechanistic studies have revealed roles for PPARA-mediated autophagy, AICD/FOXO3a signaling, Fe65 nuclear localization, ESCRT competition, and glial METTL14/DUSP1/MAPK pathways in modulating APP biosynthesis and related pathology. These findings underscore the value of CRISPR-based knockout, point-mutation, knock-in, and overexpression models for dissecting causal regulators and for developing therapeutic strategies that lower APP at its source. As Alzheimer disease biomarkers such as plasma phospho-tau217 advance into clinical use, understanding how to safely and effectively reduce APP biosynthesis will remain a central research goal. EDITGENE's CRISPR services and bioinformatics support can accelerate discovery and validation of negative regulators within this pathway.
References
- 1. Luo R et al.. 2020. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.. Autophagy 16(1):52-69 PMID: 30898012
- 2. Palmqvist S et al.. 2025. Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.. Nat Med 31(6):2036-2043 PMID: 40205199
- 3. Jiang M et al.. 2020. Amyloid precursor protein intracellular domain-dependent regulation of FOXO3a inhibits adult hippocampal neurogenesis.. Neurobiol Aging 95:250-263 PMID: 32866886
- 4. Canobbio I et al.. 2017. Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice.. Blood 130(4):527-536 PMID: 28611024
- 5. Gu F et al.. 2025. Negative interplay between HIV-1 Gag and amyloid precursor protein centers around competition for VPS4A and TSG101.. Proc Natl Acad Sci U S A 122(34):e2503988122 PMID: 40838881
- 6. Teng Y et al.. 2026. Astrocytic Mettl14 depletion enhances cognitive function by attenuating astrogliosis via the DUSP1/MAPK pathway in APP/PS1 mice: targeting neuroinflammation in Alzheimer's disease.. Mol Psychiatry 31(1):318-331 PMID: 40914755
- 7. Revol RS et al.. 2023. Alpha-secretase dependent nuclear localization of the amyloid-β precursor protein-binding protein Fe65 promotes DNA repair.. Mol Cell Neurosci 127:103903 PMID: 37918552
- 8. Larner AJ. 1995. Physiological and pathological interrelationships of amyloid beta peptide and the amyloid precursor protein.. Bioessays 17(9):819-24 PMID: 8763834
